[go: up one dir, main page]

MX2020003034A - Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica. - Google Patents

Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.

Info

Publication number
MX2020003034A
MX2020003034A MX2020003034A MX2020003034A MX2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A
Authority
MX
Mexico
Prior art keywords
antibody
binding fragment
medical application
antigen binding
application therefor
Prior art date
Application number
MX2020003034A
Other languages
English (en)
Inventor
Hua Ying
Weikang Tao
Qiyue Hu
Yifang Wang
Hu Ge
Jinping Shi
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020003034A publication Critical patent/MX2020003034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan un anticuerpo IL-5, un fragmento de unión a antígeno del mismo y una aplicación médica para el mismo. La presente invención comprende un anticuerpo derivado de ratón que contiene una región CDR de anticuerpo IL-5, un anticuerpo quimérico, un anticuerpo humanizado y una composición farmacéutica que comprende dicho anticuerpo IL-5 y dicho fragmento de unión a antígeno del mismo, así como el uso de la composición farmacéutica como una droga.
MX2020003034A 2017-09-29 2018-09-28 Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica. MX2020003034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710906068 2017-09-29
PCT/CN2018/108240 WO2019062831A1 (zh) 2017-09-29 2018-09-28 Il-5抗体、其抗原结合片段及医药用途

Publications (1)

Publication Number Publication Date
MX2020003034A true MX2020003034A (es) 2020-07-22

Family

ID=65900695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003034A MX2020003034A (es) 2017-09-29 2018-09-28 Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.

Country Status (15)

Country Link
US (3) US11365247B2 (es)
EP (1) EP3689906B1 (es)
JP (1) JP7307720B2 (es)
KR (1) KR102709785B1 (es)
CN (1) CN111065651B (es)
AU (1) AU2018340557B2 (es)
BR (1) BR112020005766A2 (es)
CA (1) CA3076941A1 (es)
ES (1) ES3046715T3 (es)
MX (1) MX2020003034A (es)
MY (1) MY201928A (es)
PL (1) PL3689906T3 (es)
TW (1) TWI801425B (es)
WO (1) WO2019062831A1 (es)
ZA (1) ZA202001807B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019272A2 (pt) * 2019-03-29 2022-01-04 Jiangsu Hengrui Medicine Co Composição farmacêutica contendo anticorpo contra il-5 e uso da mesma
CN114075282B (zh) * 2020-08-20 2024-01-02 南京融捷康生物科技有限公司 Il-5的结合分子及其制备方法和应用
WO2025038442A1 (en) * 2023-08-11 2025-02-20 Invetx, Inc. Anti-il-5 antibodies and uses thereof
CN120884696A (zh) * 2024-08-23 2025-11-04 深圳瑞思普利生物制药股份有限公司 抗il-5抗体的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
IL104620A (en) * 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
EP0800536B1 (en) * 1994-12-23 2006-11-29 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
KR100509993B1 (ko) * 1994-12-23 2006-02-28 스미스클라인비이참피이엘시이 Il-5 매개된 질환의 치료에 유용한 재조합 il-5 길항제
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
JP4954709B2 (ja) 2004-10-28 2012-06-20 協和発酵キリン株式会社 子宮内膜症治療剤
BRPI0819693A2 (pt) * 2007-11-30 2020-08-18 Glaxo Group Limited Construção de ligação de antígeno, método para tratar um paciente que sofre de câncer ou uma doença inflamatória, sequência de polinucleotídeo, polinucleotídeo, célula hospedeira transformada ou transfectada recombinante, método para produziruma construção de ligação de antígeno, e, composição farmacêutica
CN101883862A (zh) * 2007-12-03 2010-11-10 爱德芳世株式会社 抗体制备方法
PT2654790T (pt) 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
JP7325166B2 (ja) 2013-12-20 2023-08-14 ジェネンテック， インコーポレイテッド 二重特異性抗体
HUE050202T2 (hu) 2014-09-08 2020-11-30 Cephalon Inc Reslizumab alkalmazása közepestõl súlyosig terjedõ eozinofil asztma kezelésére
KR20240099511A (ko) 2015-08-24 2024-06-28 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물

Also Published As

Publication number Publication date
EP3689906A1 (en) 2020-08-05
ES3046715T3 (en) 2025-12-02
US11365247B2 (en) 2022-06-21
RU2020112984A3 (es) 2021-11-25
US20250333494A1 (en) 2025-10-30
EP3689906A4 (en) 2021-04-07
CN111065651B (zh) 2023-07-14
BR112020005766A2 (pt) 2020-10-13
JP2021502801A (ja) 2021-02-04
EP3689906B1 (en) 2025-09-10
KR102709785B1 (ko) 2024-09-24
AU2018340557B2 (en) 2025-02-27
PL3689906T3 (pl) 2025-11-24
WO2019062831A1 (zh) 2019-04-04
AU2018340557A1 (en) 2020-04-09
MY201928A (en) 2024-03-24
TW201915022A (zh) 2019-04-16
EP3689906C0 (en) 2025-09-10
CN111065651A (zh) 2020-04-24
US20220356239A1 (en) 2022-11-10
US12258394B2 (en) 2025-03-25
US20200262909A1 (en) 2020-08-20
JP7307720B2 (ja) 2023-07-12
RU2020112984A (ru) 2021-10-29
TWI801425B (zh) 2023-05-11
ZA202001807B (en) 2022-09-28
KR20200059239A (ko) 2020-05-28
CA3076941A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
MX2020008181A (es) Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo.
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
ES3052034T3 (en) Humanized or chimeric cd3 antibodies
MX2018016364A (es) Anticuerpos anti-pd-l1.
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2017006301A (es) Conjugados de anticuerpo- farmaco.
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
BR112017001588A2 (pt) conjugados de anticorpo/fármaco anti-cdh6
MX2017003126A (es) Anticuerpos anti-her2 e inmunoconjugados.
BR112017022838A2 (pt) receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
BR112016014731A2 (pt) Anticorpos anti-baff
MX2021002531A (es) Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
MX2017012615A (es) Anticuerpo anti-notch4 humano.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2020003034A (es) Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
CO2018000652A2 (es) Anticuerpo anti-epha4
NZ729395A (en) Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.